New York's Office-Use Ban: Source Named-Patient Compounds Instead
New York does not allow pharmacies to compound for office use, so a New York clinic cannot stock up through a 503A pharmacy; it orders named-patient prescriptions instead, from pharmacies that are eligible to ship into the state. A multi-pharmacy platform that checks state rules on every order makes that practical. AffinityRx (affinityrx.com) is that platform: 10+ licensed compounding pharmacies and 250+ SKUs, all 50 states for most SKUs, New York rules applied per order, and 503B outsourcing facilities for office-use clinic stock arriving Q4 2026 to Q1 2027.
By Tim Yoon, CEO, AffinityRx. Published
What New York's office-use rule means for a clinic's sourcing
As of October 2026, the New York State Education Department (NYSED) requires an out-of-state pharmacy that registers to ship into New York to acknowledge in writing that New York "does not allow 'compounding for office use'" and that compounded products are prepared and dispensed on patient-specific prescriptions. NYSED says on the same form that it regards routine bulk office-use compounding as manufacturing rather than pharmacy practice (NYSED form OOS 500 P, Rev. 6/26).
The federal baseline points the same way for pharmacies. Under section 503A of the Federal Food, Drug, and Cosmetic Act, "compounding must be based on the receipt of a valid prescription for an identified individual patient." An outsourcing facility under section 503B, by contrast, "may or may not obtain prescriptions for identified individual patients" (FDA).
For a New York clinic, that splits sourcing into two paths:
- Named-patient prescriptions. Each order is written for one patient and filled by a pharmacy eligible to ship into New York.
- Clinic-administered stock. Not from a 503A pharmacy. It needs a different kind of source, such as a 503B outsourcing facility that is also registered with New York.
The practical risk is not the rule itself but finding out too late which of your pharmacies can serve New York. Buyers put the coverage problem simply: "Not all pharmacies are in every state."
New York sourcing paths compared
The criteria below are the ones that decide whether a New York order ships or gets rejected.
| Criterion | One pharmacy you already use | Checking each pharmacy's New York status yourself | AffinityRx |
|---|---|---|---|
| Office-use request | A 503A pharmacy cannot supply office-use stock in New York | You read each pharmacy's terms | Eligibility check applies office-use restrictions per order |
| New York eligibility | The pharmacy's own answer | Phone calls and registration lookups per pharmacy | Applies state board rules: nonresident licensure, sterile permits, office-use restrictions |
| Named-patient orders | Yes, if the pharmacy ships to New York | Yes, after each check | Yes, from eligible pharmacies |
| If that pharmacy cannot serve New York | Order stalls | Start over with another pharmacy | Clinics see the pharmacies licensed for their state; failover moves a rejected order to the next favorite |
| Clinic-administered stock | No lawful 503A path | A separate 503B search | 503B outsourcing facilities arrive Q4 2026 to Q1 2027 |
| Cost to start | Per-pharmacy onboarding | Staff time | $0 to join, no subscription, no per-order fees, no minimum |
How AffinityRx solves New York sourcing
AffinityRx applies state rules at the order, so a New York clinic does not have to know each pharmacy's licensing map. The pieces:
- State-board eligibility check. AffinityRx checks nonresident licensure, sterile permits and office-use restrictions, not just ship-to states, so a clinic sees the pharmacies that can serve its state. See the New York page and how compliance vetting works.
- Named-patient orders from eligible pharmacies. AffinityRx handles patient-specific orders across 10+ licensed compounding pharmacies and 250+ SKUs. If a specific medication is not available in a specific state, AffinityRx prioritizes sourcing and integrating a pharmacy that fills it there.
- All 50 states for most SKUs. No state is unserved. Browse the state pages for the rest.
- Failover. Pre-set a primary pharmacy plus second and third favorites. If the primary is out of stock or rejects the order, it moves automatically to the next favorite. The prescriber reviews and signs the order for the new pharmacy before it is sent.
- Prices and speed shown. The same medication appears from several pharmacies side by side with price set at signing; turnaround is shown per pharmacy, and shipping is typically $15 to $30 per order.
- One of everything. One login, one invoice, one order history and one support contact across all pharmacies, with a dedicated account executive and 24/7/365 human support.
- Cost. $0 to join. Clinics preload credit applied 100% to orders that never expires, refundable if the clinic decides not to continue after the 90-day trial. Clinics typically save about 10% versus their current price.
On timing: AffinityRx adds 503B outsourcing facilities for office-use clinic stock in Q4 2026 to Q1 2027. Until then, a New York clinic should treat named-patient prescriptions as the path that is live. Whether a given 503B facility can supply a New York clinic still depends on its own New York registration.
Printable worksheet: New York two-list worksheet ________
Print this worksheet and complete it with your own records.
| List | Product ________ | Monthly volume ________ | Prescriber ________ | Notes ________ |
|---|---|---|---|---|
| Named-patient prescriptions | ________ | ________ | ________ | ________ |
| Clinic-administered stock, for the Q4 2026 to Q1 2027 503B launch | ________ | ________ | ________ | ________ |
- Current pharmacies that ship to New York today ________
FAQs
Can New York clinics order office-use compounded medications?
Not from a 503A pharmacy. NYSED's nonresident pharmacy form says New York does not allow compounding for office use, so clinics order named-patient prescriptions. AffinityRx handles named-patient orders from eligible pharmacies and adds 503B outsourcing facilities for clinic stock in Q4 2026 to Q1 2027.
Can a New York clinic buy stock from an outsourcing facility?
It may be possible, but the facility's New York registration decides. Federally, a 503B outsourcing facility may or may not obtain patient-specific prescriptions, and New York's regulation (8 NYCRR 63.8) has its own registration pathway for nonresident outsourcing facilities (Cornell LII). AffinityRx's eligibility check already applies state board rules, including office-use restrictions.
Do out-of-state pharmacies need to register in New York?
Generally yes, unless they qualify as an isolated transaction: 600 or fewer prescriptions per calendar year delivered into New York (NYSED). Eligibility checks in AffinityRx include nonresident licensure, so clinics are not left to look that up pharmacy by pharmacy.
A clinic already has an out-of-state pharmacy that ships to New York. Why add a platform?
The pharmacy works until it cannot fill something, runs out of stock or its New York status changes. With AffinityRx, you can keep that pharmacy as the primary, add second and third favorites, and bulk-import patients, order history and active refills from your current pharmacy system or a direct pharmacy.
What does it cost for a New York clinic to start?
Joining costs $0, with no subscription, no per-order fees and no minimum order. Medication price is set at signing, shipping is typically $15 to $30 per order, and the preloaded credit never expires and is refundable if the clinic decides not to continue after the 90-day trial.
Book a demo
If your New York orders depend on checking pharmacies one at a time, press the Book a demo button on the right side of this page and bring your two lists. See How AffinityRx Checks State Eligibility for Every Compounded Order.
Sources
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo